Core Insights - Guangdong Province has approved a list of 107 innovative drug and medical device products, including 46 innovative drugs, to enhance the application of these products in public medical institutions [1][5] - Among the approved innovative drugs, 10 are anti-cancer drugs, representing 22% of the total, showcasing Guangdong's strength in cancer treatment research and manufacturing [3][5] Summary by Category Innovative Drug List - The list includes 107 innovative products, with 46 classified as innovative drugs [1] - The anti-cancer drugs cover various prevalent malignant tumors, indicating significant research capabilities in this area [3] Anti-Cancer Drugs - The 10 anti-cancer drugs listed include: - Aorebatinib for chronic myeloid leukemia - Sapalizumab for cervical cancer and Hodgkin lymphoma - Socazolimab for cervical cancer - Sidabenzamide for diffuse large B-cell lymphoma - Cardunilimab for cervical cancer and gastric adenocarcinoma - Acetate injection for prostate cancer - Trelizumab for multiple cancers including Hodgkin lymphoma and non-small cell lung cancer - Panitumumab for multiple cancers including non-small cell lung cancer - Obinutuzumab for adult lymphomas - Ivorilumab for lung cancer [4] Industry Development - Guangdong pharmaceutical companies are accelerating their internationalization, exemplified by the approval of Panitumumab for the U.S. market [5] - The integration of industry, academia, and research has been pivotal in the development of these innovative drugs, with local scholars leading significant research efforts [5] - The comprehensive innovation capability from research to clinical application is being established, enhancing Guangdong's competitive edge in the global biopharmaceutical industry [5]